Long term serological surveillance after treatment of Helicobacter pylori infection.

Veenendaal, R.A.; Peña, A. S.; Meijer, J. L.; Endtz, Hubert P.; Est, M. M. C. van der; Duijn, Wim van; Eulderink, F; Kreuning, J; Lamers, C. B. H. W.

doi:10.1136/gut.32.11.1291

Cited by 100 publications

(58 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, we believe that active immunization is required for protection against reinfection if a relatively high dose of the bacteria is used for challenge. These results have implications for the development of vaccines against H. pylori infection in areas where H. pylori infection is endemic, such as developing countries where reinfection with a presumably large inoculum may occur (9,22,32).…”

Section: Discussionmentioning

confidence: 99%

Protection against ExperimentalHelicobacter pyloriInfection after Immunization with InactivatedH. pyloriWhole-Cell Vaccines

et al. 2002

View full text Add to dashboard Cite

The protective effect of therapeutic oral immunization with homologous and heterologous formalin-inactivated Helicobacter pylori cells given together with cholera toxin as an adjuvant was evaluated with C57BL/6 mice infected with H. pylori Sydney strain 1 (SS1). The bacteria used for immunization were strains that were either homologous or heterologous with regard to the O antigen (i.e., the Lewis antigen [Le antigen]) expressed by the lipopolysaccharide of the infecting H. pylori SS1 strain. We found that repeated oral immunization with inactivated H. pylori SS1 cells can significantly inhibit an existing infection (P < 0.001) and that the protection induced by such therapeutic immunization extends to protection against reinfection (P < 0.001). A similar level of protection was also achieved by immunization with another inactivated H. pylori strain having the same O antigen (Le antigen) as the infecting H. pylori SS1 strain. In contrast, immunization with inactivated strains expressing a heterologous O antigen, Le x , provided less protection or no protection. Immunization with H. pylori lysate preparations, on the other hand, resulted in significant comparable protection whether the lysates were prepared from an Le x strain or an Le y strain. Postimmunization gastritis was seen in mice that were protected after vaccination but not in unimmunized or unprotected mice. In conclusion, therapeutic immunization with inactivated H. pylori whole-cell vaccines may provide strong protection both against experimental H. pylori infection and against later reinfection.

show abstract

Section: Discussionmentioning

confidence: 99%

Protection against ExperimentalHelicobacter pyloriInfection after Immunization with InactivatedH. pyloriWhole-Cell Vaccines

et al. 2002

View full text Add to dashboard Cite

show abstract

“…In areas where H. pylori infection is endemic, a situation found in many developing and transitional countries, the populations are at a high risk of acquiring reinfections (17,30,38,41). This makes it important to also determine protection against reinfection after antibiotic treatment of the primary infection, either as a result of an immunizing effect of the primary infection or after specific vaccination.…”

Section: Discussionmentioning

confidence: 99%

“…Although recurrence rates after antimicrobial therapy were earlier reported to be low, this may be more due to the low exposure rates and opportunity for reinfection in the patient groups monitored than to the existence of effective immunity as a result of the previous infection. Indeed, in areas where there is a higher risk for H. pylori infection, true reinfections are found to be a serious problem (17,30,38,41).…”

mentioning

confidence: 99%

Effects of Oral Vaccination and Immunomodulation by Cholera Toxin on ExperimentalHelicobacter pyloriInfection, Reinfection, and Gastritis

2002

View full text Add to dashboard Cite

Therapeutic vaccination is an attractive strategy to control infection and disease caused by Helicobacter pylori. In mice infected with H. pylori we have studied the protective effect of oral immunization with an H. pylori lysate preparation given together with the mucosal adjuvant cholera toxin (CT), both against the initial infection and against a later reinfection challenge. We have also examined the effects of treatment with the CT adjuvant alone on H. pylori infection and reinfection. Specific immunization with lysate was found to result in a sixfold reduction of the extent (bacterial load) of the primary infection and also to provide similar levels of protection against reinfection. However, these effects were associated with severe postimmunization gastritis. In contrast, oral treatment with CT alone at the time of initial infection, while unable to suppress the initial infection, gave rise to a 20-fold reduction in bacterial load upon reinfection without causing any associated gastric inflammation. Both the infected animals that were specifically immunized and those that were treated with CT only displayed increased in vitro proliferative responses of mononuclear cells to H. pylori antigens. Antibody levels in response to H. pylori were on the other hand only marginally increased after treatment with CT, whereas they were markedly elevated after immunization with lysate plus CT, with a rise in both (Th2-driven) immunoglobulin G1 (IgG1) and, especially, (Th1-driven) IgG2a antibodies. The results illustrate the complex balance between protection and harmful inflammation after postinfection vaccination against H. pylori as studied in a mouse model.

show abstract

“…The presence of H. pylori antibodies indicates current infection with reasonable accuracy, except in individuals recently cleared of the infection, due to the persistence of elevated antibody levels for some months after clearance (Kosunen et al, 1992;Veenendaal et al, 1991). Infants born to H. pylori-infected mothers appear to have passively acquired H. pylori IgG antibodies that disappear within the first months of life (Blecker et al, 1994).…”

Section: Introductionmentioning

confidence: 99%

Implications of Helicobacter pylori infection for stomach cancer prevention

Goodman¹

1997

Cad. Saúde Pública

View full text Add to dashboard Cite

Long term serological surveillance after treatment of Helicobacter pylori infection.

Cited by 100 publications

References 16 publications

Protection against ExperimentalHelicobacter pyloriInfection after Immunization with InactivatedH. pyloriWhole-Cell Vaccines

Protection against ExperimentalHelicobacter pyloriInfection after Immunization with InactivatedH. pyloriWhole-Cell Vaccines

Effects of Oral Vaccination and Immunomodulation by Cholera Toxin on ExperimentalHelicobacter pyloriInfection, Reinfection, and Gastritis

Implications of Helicobacter pylori infection for stomach cancer prevention

Contact Info

Product

Resources

About